Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases. Traditional discovery methods have proven unable to identify the targets of immune response. ATLAS, Genocea's proprietary technology platform, mimics the human immune system to identify the targets most likely to illicit an immune response. Genocea's pipeline of novel, clinical-stage, T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for pneumococcus, and earlier-stage programs in chlamydia, malaria and cancer immunotherapy.
Biology Biochemistry
Advancing Human Health
Lux founded: 2006
IPO (NASDAQ: GNCA) 2014